MX2021003929A - Compuestos farmaceuticos. - Google Patents

Compuestos farmaceuticos.

Info

Publication number
MX2021003929A
MX2021003929A MX2021003929A MX2021003929A MX2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
tyk2 kinase
compounds
sup
tyk2
Prior art date
Application number
MX2021003929A
Other languages
English (en)
Spanish (es)
Inventor
John Charles Reader
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of MX2021003929A publication Critical patent/MX2021003929A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021003929A 2018-10-08 2019-10-07 Compuestos farmaceuticos. MX2021003929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds
PCT/EP2019/077118 WO2020074461A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2021003929A true MX2021003929A (es) 2021-06-04

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003929A MX2021003929A (es) 2018-10-08 2019-10-07 Compuestos farmaceuticos.

Country Status (18)

Country Link
US (1) US12187716B2 (https=)
EP (1) EP3864009B1 (https=)
JP (1) JP7383030B2 (https=)
KR (1) KR102844196B1 (https=)
CN (1) CN113056456B (https=)
AU (1) AU2019359320B2 (https=)
BR (1) BR112021006424A2 (https=)
CA (1) CA3111049A1 (https=)
DK (1) DK3864009T3 (https=)
ES (1) ES3021420T3 (https=)
FI (1) FI3864009T3 (https=)
GB (1) GB201816369D0 (https=)
IL (1) IL281599B2 (https=)
MX (1) MX2021003929A (https=)
PL (1) PL3864009T3 (https=)
PT (1) PT3864009T (https=)
SG (1) SG11202102490TA (https=)
WO (1) WO2020074461A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス, インコーポレイテッド Tyk2分解剤およびそれらの使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
ATE394102T1 (de) 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
CN100400040C (zh) 2000-10-30 2008-07-09 詹森药业有限公司 三肽酶抑制剂
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
ES2395581T3 (es) 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
US8278335B2 (en) 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
WO2009155156A1 (en) 2008-06-18 2009-12-23 Merck & Co., Inc. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2793024A1 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20140228349A1 (en) 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
RU2652795C2 (ru) * 2013-09-03 2018-05-03 Сареум Лимитед Производные 2-фенил-оксазол-4-карбоксамида, модулирующие активность jak и tyk2 киназ
JP6310767B2 (ja) 2014-05-13 2018-04-11 日本電子株式会社 自動分析装置及びノズル洗浄方法
NO2721710T3 (https=) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Also Published As

Publication number Publication date
BR112021006424A2 (pt) 2021-07-06
AU2019359320B2 (en) 2024-04-04
DK3864009T3 (da) 2025-03-17
EP3864009A1 (en) 2021-08-18
CN113056456B (zh) 2023-06-13
JP7383030B2 (ja) 2023-11-17
KR102844196B1 (ko) 2025-08-07
US12187716B2 (en) 2025-01-07
US20210387981A1 (en) 2021-12-16
IL281599B1 (en) 2024-06-01
ES3021420T3 (en) 2025-05-26
PT3864009T (pt) 2025-04-23
FI3864009T3 (fi) 2025-03-24
GB201816369D0 (en) 2018-11-28
IL281599A (en) 2021-05-31
CA3111049A1 (en) 2020-04-16
PL3864009T3 (pl) 2025-04-22
SG11202102490TA (en) 2021-04-29
WO2020074461A1 (en) 2020-04-16
KR20210076036A (ko) 2021-06-23
EP3864009B1 (en) 2025-02-19
CN113056456A (zh) 2021-06-29
AU2019359320A1 (en) 2021-03-18
JP2022514799A (ja) 2022-02-15
IL281599B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
GEAP202315746A (en) Protein tyrosine phosphatase inhibitors
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MA55145B1 (fr) Polythérapie incluant un inhibiteur de kras g12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2021004431A (es) Procesos novedosos.
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX379459B (es) Inhibidores de bromodominios.
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
ZA202006071B (en) Antiproliferation compounds and uses thereof
NZ754922A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
MX2021003929A (es) Compuestos farmaceuticos.
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.